Pharma/Biotech - Page 1 | TalkMarkets

Content

All Posts > Content under Pharma/Biotech
1 to 16 of 5488 Posts
1 2 3 ... 343 >>>
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Article By: ChinaBio® Today
Saturday, June 15, 2024 1:40 PM EDT
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi raised $126.8 million in a Hong Kong IPO.
In this article: KYKOF, SGIOF, ZYME, TAK, ASPHF Also: BGNE
Read
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
Article By: The Tokenist
Friday, June 14, 2024 4:00 PM EDT
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist.
In this article: RCKT, ARVN, OCUP
Read
Chart Of The Day: Avidity Biosciences - Something's Up?
Article By: Jim Van Meerten
Friday, June 14, 2024 10:20 AM EDT
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics.
In this article: RNA
Read
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Article By: Rod Raynovich
Monday, June 10, 2024 10:37 PM EDT
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services.
In this article: AZN, MRK, UNH, XBI, XLV, XLC, VRTX
Read
In The Zone: Neurofeedback And Our Trading Impulses
Article By: Brett N. Steenbarger, Ph.D.
Monday, June 10, 2024 1:13 AM EDT
Neurofeedback is a real time score card for self control.
Read
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
Article By: Lorimer Wilson
Monday, June 10, 2024 12:35 AM EDT
The global "AI in drug discovery" market was worth $1.1B last year and is expected to expand by a CAGR of 30% between now and 2030 leading to 50 novel therapies over the next decade, with annual sales in excess of $50 billion
In this article: EXAI, SDGR, ABCL, RLAY, ABSI, RXRX
Read
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Article By: Lorimer Wilson
Sunday, June 9, 2024 5:44 PM EDT
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.
In this article: ATAI, MNMD, CMPS, GHRS
Read
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Article By: ChinaBio® Today
Saturday, June 8, 2024 2:20 PM EDT
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent BioPharma.
In this article: SMMT, IMAB, GNNSF, GPCR, ASPHF, AVBP, AKESF Also: AZN, BMY
Read
Large Cap BIopharmaceuticals Overview
Article By: Rod Raynovich
Monday, June 3, 2024 5:44 PM EDT
As a defensive play healthcare is weighted at about 12% of the S&P 500.
In this article: AZN, GSK, LLY, MRK, PFE, IBB, SGEN, GILD, VRTX
Read
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Article By: ChinaBio® Today
Saturday, June 1, 2024 3:20 PM EDT
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.
In this article: AHKSF, BAYRY, CALT, BNTX, BNR, AKESF, GYRE Also: MRK, SMMT
Read
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Article By: ChinaBio® Today
Saturday, May 25, 2024 4:00 PM EDT
Jiangsu Hengrui Medicine out-licensed global rights for its portfolio of three proprietary GLP-1 candidates to a US startup, Hercules, in a deal worth up to $6 billion. Hengrui will receive $110 million upfront and up to $200 million in milestones.
In this article: AZN, BGNE, TAK, IVBXF, CSPHF
Read
Large Cap Biopharmaceuticals Performance
Article By: Rod Raynovich
Monday, May 20, 2024 2:00 PM EDT
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​.
In this article: AZN, BMY, MRK, PFE, IBB, REGN, BIIB, GILD, XLV
Read
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
Article By: ChinaBio® Today
Sunday, May 19, 2024 7:14 PM EDT
In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones.
In this article: SLGL, TAK
Read
For Biotech Stocks To Move Higher, This Must Move Lower
Article By: Tarun Chandra, CFA
Wednesday, May 15, 2024 5:26 AM EDT
While biotechs have significantly lagged behind the broader market, there is reason to be optimistic once inflation-related volatility subsides. IBB and XBI present good vehicles for biotech exposure.
In this article: IBB, XBI
Read
Chart Of The Day: Kewaunee Scientific - New All Time High
Article By: Jim Van Meerten
Tuesday, May 14, 2024 12:34 PM EDT
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products.
In this article: KEQU
Read
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
Article By: The Tokenist
Monday, May 13, 2024 2:00 PM EDT
In the last three months, IBRX outperformed NVDA by over 3x.
In this article: IBRX Also: LEGN
Read
1 to 16 of 5488 Posts
1 2 3 ... 343 >>>